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OBJECTIVE — We examined metabolic changes in the period immediately after the diagno-
sis of type 1 diabetes and in the period leading up to its diagnosis in Diabetes Prevention
Trial–Type 1 (DPT-1) participants.
RESEARCH DESIGN AND METHODS — The study included oral insulin trial partic-
ipants and parenteral insulin trial control subjects (n  63) in whom diabetes was diagnosed by
a 2-h diabetic oral glucose tolerance test (OGTT) that was conﬁrmed by another diabetic OGTT
within3months.DifferencesinglucoseandC-peptidelevelsbetweentheOGTTswereassessed.
RESULTS — Glucose levels increased at 90 (P  0.006) and 120 min (P  0.001) from the
initialdiabeticOGTTtotheconﬁrmatorydiabeticOGTT(meanSDinterval5.52.8weeks).
Peak C-peptide levels fell substantially between the OGTTs (median change 14.3%, P 
0.001). Among the 55 individuals whose last nondiabetic OGTT was 6 months before the
initial diabetic OGTT, peak C-peptide levels decreased between these two OGTTs (median
change 14.0%, P  0.052). Among those same individuals the median change in peak C-
peptidelevelsfromthelastnormalOGTTtotheconﬁrmatoryOGTT(interval7.51.3months)
was23.8%(P0.001).MedianratesofchangeinpeakC-peptidelevelswere0.00ng ml
1 
month
1 (P  0.468, n  36) from 12 to 6 months before diagnosis, 0.10 ng   ml
1  
month
1 (P  0.059, n  55) from 6 months before diagnosis to diagnosis, and 0.43
ng   ml
1   month
1 (P  0.002, n  63) from the initial diabetic OGTT to the conﬁrmatory
diabetic OGTT.
CONCLUSIONS — It seems that postchallenge C-peptide levels begin to decrease apprecia-
bly in the 6 months before diagnosis and decrease even more rapidly within 3 months after
diagnosis.
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E
vidence suggests that there is pro-
gressive metabolic dysfunction be-
fore and after the diagnosis of type 1
diabetes. A considerable number of in-
dividuals who develop type 1 diabetes
appear to have a gradual metabolic de-
terioration (1–3) within 6 months of di-
agnosis, after which the deterioration
becomes more rapid (4). After diagno-
sis, there also appears to be a progres-
sive loss of insulin secretion (5–8).
However,evidenceforthislosshasbeen
derived from studies performed within
a clinical context. Individuals were as-
sessed after their diabetes was diag-
nosed by clinical presentation and after
therapeutic measures were initiated.
There are no studies that have followed
changesininsulinsecretionfrombefore
the diagnosis of type 1 diabetes to im-
mediately after its diagnosis in humans.
Such information would be highly use-
ful for gauging how quickly interven-
tionsshouldbeimplementedtodelayor
prevent the loss of insulin secretion in
type 1 diabetes. Interventions that are
initiated before a substantial loss of in-
sulin secretion occurs could be more
efﬁcacious.
TheDiabetesPreventionTrial–Type1
(DPT-1) provides unique data for exam-
ining insulin secretion in the early stages
oftype1diabetes(9,10).Oralglucosetol-
erance tests (OGTTs) were performed ev-
ery 6 months for diagnostic surveillance,
so that the diagnosis of type 1 diabetes
would be captured very close to onset.
Also, in participants who had OGTTs in
the diabetic range, type 1 diabetes was
conﬁrmedwithrepeatOGTTs.Thesetwo
features of the DPT-1 data were used to
determine the rate and extent of meta-
bolicdeteriorationthatoccursintheperi-
onset period of type 1 diabetes.
RESEARCH DESIGN AND
METHODS— Sixty-three partici-
pants of the parenteral and oral insulin
DPT-1 trials whose diabetes was diag-
nosed with two consecutive diabetic 2-h
OGTTs (initial and conﬁrmatory) are in-
cluded in the analyses. Those in the inter-
vention arm of the parenteral insulin trial
(n  41) were excluded because the par-
enteral insulin was received (as per pro-
tocol) between the two diabetic OGTTs.
Also excluded were those (n  8) whose
interval between the two OGTTs was
greater than 3 months. The algorithm for
determining risk in the DPT-1 has been
described previously (9). The presence of
islet cell autoantibodies was required for
entry into both trials. Participants were
considered to have a 5-year risk above
50% and be eligible for the parenteral
insulin trial if either the ﬁrst-phase in-
sulin response on intravenous glucose
tolerance testing was below a deﬁned
threshold and/or there were OGTT ab-
normalities. If those metabolic criteria
were not present but insulin autoanti-
bodieswerepositive,the5-yearriskwas
considered to be 26–50% and partici-
pants were eligible for the oral insulin
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fect in either trial.
Procedures
Participants in the parenteral insulin trial
intervention group received recombinant
human ultralente insulin, whereas those
intheoralinsulintrialinterventiongroup
received recombinant human insulin
crystals. OGTTs were performed at
6-month (3 months) intervals in both
trials.Allstudytreatmentsweretobesus-
pended for 3 days before the OGTT. The
dose of oral glucose was 1.75 g/kg (max-
imum, 75 g carbohydrate). Samples were
obtained for plasma glucose and C-
peptide measurements in the fasting state
and at 30, 60, 90, and 120 min. Insulin
measurementswerenotobtainedbecause
there was concern over the formation of
insulin autoantibodies. Individuals with
glucose values in the diabetic range at a
routine visit were asked to return for con-
ﬁrmation by an OGTT within 60 days
(some returned beyond 60 days) unless
an OGTT was clinically contraindicated.
Participants were to continue the same
studyregimentheyhadbeenusingbefore
the initial diabetic OGTT. The age at the
ﬁrst of the diabetic OGTTs was consid-
ered the age at diagnosis. The thresholds
for diabetes were fasting glucose values
126 mg/dl and/or 2-h glucose values
200 mg/dl.
Laboratory measures. Plasma glucose
levelsweremeasuredbytheglucoseoxidase
method.C-peptidelevelsweremeasuredby
radioimmunoassay. The interassay coefﬁ-
cient of variation for the C-peptide assay
was 6.9% in a reference pool with relatively
high values and 7.8% in a reference pool
with relatively low values. Fasting C-
peptide values in the undetectable range
(0.2 ng/ml) were assigned a value of 0.1
ng/ml for the analyses.
Data analysis
The statistical signiﬁcance of percent
change against a null hypothesis of no
change was assessed with signed-rank
tests. Pearson correlations and linear re-
gression were used to assess associations.
Values for rates of change in peak C-
peptidewereobtainedbydividingthedif-
ference in peak C-peptide values for an
interval by the length of the interval.
OGTTareasunderthecurve(AUCs)were
calculated with the trapezoidal rule. Des-
ignated time intervals before diagnosis
were within 3 months. SAS (version
9.1.3; SAS Institute, Cary, NC) was used
for the analyses. All P values are two
sided.
RESULTS— Sixty-threeDPT-1partic-
ipants (51% female) are included in the
analyses. All had a complete OGTT in the
diabetic range that was conﬁrmed by a
second complete OGTT within an inter-
val of 3 months. Of these, 31 were in the
parenteral insulin trial and 32 were in the
oral insulin trial (15 in the intervention
group). The mean  SD age at the ﬁrst
diabetic OGTT was 13.2 6.9 years. The
mean interval between the diabetic
OGTTs was 5.5  2.8 weeks.
Table 1 shows glucose levels for the
initial and conﬁrmatory OGTTs. There
was a tendency for glucose levels to in-
crease between the ﬁrst diabetic OGTT
andtheconﬁrmatorydiabeticOGTTwith
statistically signiﬁcant increases at 90
(P  0.006) and 120 min (P  0.001)
and for AUC glucose (P  0.016). Figure
1A shows the corresponding percent
changes.
Table2showstheC-peptidelevelsfor
the initial and conﬁrmatory OGTTs.
There were signiﬁcant declines in C-
peptide levels at each postchallenge time
point and for AUC and peak C-peptide
values (P  0.01 for all). Figure 1B shows
the corresponding percent changes. The
medianpercentchangeinpeakC-peptide
levels was 14.3% (P  0.001). There
was less of a decline in fasting C-pep-
tidelevels(6.7%,P0.416).Whenthe
fasting C-peptide–to–fasting glucose and
the AUC C-peptide–to–AUC glucose ra-
tioswereexamined,percentchangeswere
appreciableforboththeformer(10.3%,
P  0.046) and the latter (16.7%, P 
0.001).
The change in AUC glucose values
betweenthetwodiabeticOGTTswaspos-
itively associated with the length of the
interval between them (r  0.32, P 
0.011), whereas there was an inverse cor-
relation of change of peak C-peptide lev-
els with that interval (r  0.31, P 
0.014). Thus, the fall in peak C-peptide
levels increased with longer intervals. A
scatter plot for the association of the
change in peak C-peptide levels between
the OGTTs and the interval between the
diabetic OGTTs (with the removal of an
outlier)isshowninFig.2.Thecorrelation
was almost identical (r  0.31, P 
0.016)withtheoutlierexcluded.Withan
allowance for the peak C-peptide levels
fromtheﬁrstdiabeticOGTT,theslopefor
the association of change in peak C-
peptide levels with the interval between
thediabeticOGTTswas0.56ng ml
1 
month
1.
Of the 63 individuals included in the
analysis, 55 had an OGTT 6 months
before the initial diabetic OGTT. The me-
dian percent change for the peak C-
peptideinthatintervalwas14.0%(P
0.052). The percent change in the peak
C-peptide from the last nondiabetic
OGTT to the second diabetic OGTT
(mean  SD interval 7.5  1.3 months)
was 23.8% (P  0.001). The AUC C-
peptide–to–AUC glucose percent change
was even more marked (45.7%, P 
0.001) in that interval.
Figure 3 shows the median rates of
change in peak C-peptide levels over in-
tervalsintheperionsetperiod.Thevalues
were obtained by dividing the difference
in peak C-peptide values for an interval
by the length of the interval. There was
minimal change (0.00 ng   ml
1  
month
1, P  0.468, n  36) in peak
C-peptide from 12 to 6 months before
diagnosis. There was a decline in peak C-
peptidelevelsfrom6monthsbeforediag-
nosis to diagnosis (0.10 ng   ml
1  
month
1,P0.059,n55)andaneven
greater rate of decline from diagnosis to
within 3 months after diagnosis (0.43
ng   ml
1   month
1, P  0.002, n  63).
Table 1—Glucose values of initial and conﬁrmatory diabetic OGTTs
Glucose (mg/dl)
P value First OGTT
Conﬁrmatory
OGTT
Fasting 106 (91, 115) 107 (98, 119) 0.117
30 min 195 (168, 217) 194 (170, 216) 0.760
60 min 241 (208, 267) 254 (222, 283) 0.089
90 min 253 (234, 284) 279 (238, 310) 0.006
120 min 246 (212, 280) 283 (243, 332) 0.001
AUC (2-h)* 25.6 (24.0, 28.2) 27.5 (24.2, 31.1) 0.016
Data are medians (25th, 75th percentiles). n  63. *10
3.
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report show that, on average, C-peptide
levels decreased substantially in the inter-
val from diagnosis to 3 months after diag-
nosis. These changes occurred even with
glucose levels still in a range associated
with minimal or no symptoms.
We previously examined metabolic
progression before diagnosis in DPT-1
participants (4). In that report, peak C-
peptide levels were consistent during a
period of 30 to 6 months before diag-
nosis, after which levels declined. This
report extends observations to the post-
Figure 1—A: Percent changes in glucose indexes after diagnosis. Shown are the medians for the percent changes of glucose indexes from the initial
diabetic OGTT to the conﬁrmatory diabetic OGTT. Glucose levels tended to increase, especially at the later time points of the OGTT. B: Percent
changes in C-peptide indexes after diagnosis. Shown are the medians for the percent changes of C-peptide indexes from the initial diabetic OGTT to
the conﬁrmatory diabetic OGTT. With the exception of the fasting C-peptide, there was a 10% median decline for all of the indexes.
Table 2—C-peptide values of initial and conﬁrmatory diabetic OGTTs
C-peptide (ng/ml)
P value First OGTT Conﬁrmatory OGTT
Fasting 1.5 (0.7, 2.1) 1.2 (0.8, 1.7) 0.054
30 min 2.6 (1.9, 4.0) 2.2 (1.6, 3.5) 0.001
60 min 3.1 (2.1, 4.5) 2.7 (1.9, 3.8) 0.001
90 min 3.6 (2.3, 5.3) 3.0 (2.1, 4.3) 0.001
120 min 3.5 (2.5, 5.5) 3.2 (2.1, 5.0) 0.004
Peak 3.8 (2.7, 5.9) 3.2 (2.2, 5.0) 0.001
AUC (2-h) 350 (249, 501) 309 (212, 443) 0.001
Data are medians (25th, 75th percentiles). n  63.
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is an acceleration of postchallenge C-
peptide loss once glucose levels are in the
diabetic range. The median decline of
23.8% in peak C-peptide levels from
the last nondiabetic OGTT to the conﬁr-
matory OGTT indicates that there is a
marked loss of insulin secretion in the
perionsetperiod.Theextenttowhichthis
loss is reversible cannot be determined
from the data.
Estimates for the rate of change of
peakC-peptidelevelsinthepostdiagnosis
period were obtained in two ways. In one
approach (Fig. 2) a regression analysis was
used, whereas in the other approach (Fig.
3), the estimate was derived from an analy-
sis based on rate of change calculated for
each individual. The rate of decline was
substantial with either approach.
Glucose levels seem to have been
maintained relative to the decline in C-
peptide levels after diagnosis. This sug-
gests the possibility that compensatory
Figure 2—Association between change in peak C-peptide and time after diagnosis. Shown is the scatter plot for the association between the change
inpeakC-peptidelevelsandthetimeafterdiagnosis.Theamountofdeclinebecomesmoresubstantialwithincreasingtimeafterdiagnosis.(Anoutlier
was removed with a change in peak C-peptide of 8.8 ng/ml and a time after diagnosis of 8.0 weeks [r  0.31, P  0.014 with the outlier
included.])WhenanallowancewasmadeforthepeakC-peptideattheﬁrstdiabeticOGTT,theslopeforthedifferenceinpeakC-peptideversustime
after diagnosis was 0.56 ng   ml
1   month
1.
Figure 3—Rates of change in peak C-peptide in the perionset period. Shown are the rates of change of peak C-peptide levels according to intervals
before and after diagnosis. C-peptide levels changed minimally between 12 and 6 months before diagnosis. There was a decline in the 6 months
before diagnosis that was more substantial in the period after diagnosis.
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at play, such as an increase in insulin sen-
sitivity. Because C-peptide levels are only
indicative of insulin secretion, it is also
possible that a slowing of insulin degra-
dation could have contributed to the
maintenance of glucose levels.
For calculations of the rate of change
in peak C-peptide levels, it was assumed
that the rate of change was constant
throughout the interval. This assumption
is of particular importance in the interval
from 6 months before diagnosis to diag-
nosis,asonecannotdiscernfromthedata
thepatternofC-peptidedeclinewithinthat
period. Thus, the rate of decrease in C-
peptide may be more rapid closer to diag-
nosis and similar to the rate of decline in
C-peptideafterdiagnosis.Also,itshouldbe
emphasized that the average change pro-
vides an overall picture; individual patterns
of change vary considerably.
Participation in the DPT-1 trials
could have inﬂuenced the ﬁndings. How-
ever, we excluded those receiving paren-
teral insulin from the analyses, and there
was no overall effect from either insulin
intervention. Knowledge of the results of
the ﬁrst diabetic OGTT could have re-
sulted in lifestyle changes (11) or perhaps
even have caused some to attempt to
lower glucose levels with medication.
Still, it is doubtful that such interventions
would explain the large degree of C-
peptide loss.
No prior studies have examined met-
abolic changes from before diagnosis to
after diagnosis with OGTT surveillance.
Also, no studies have assessed metabolic
changes in individuals with newly diag-
noseddiabetesasclosetotheonsetoftype1
diabetes. C-peptide levels appear to be
much lower when type 1 diabetes is clini-
cally diagnosed (12–14) than when it is di-
agnosed through OGTT surveillance. It is
important to emphasize that of all individ-
ualsinwhomtype1diabeteswasdiagnosed
in the DPT-1, 75% were asymptomatic (9).
How our observations relate to the rate of
decline of insulin secretion in symptomatic
patientswithclinicallydiagnoseddiabetes
is unknown. Studies of patients with clin-
ically diagnosed diabetes suggest that
there is a progressive loss of insulin secre-
tionthatcanbedecreasedbyeffectiveglu-
cose control (15,16).
The marked rate of decline of C-
peptidelevelsintheperionsetperiodpro-
vides a strong rationale for developing
earlyinterventionstopreventordelaythe
progression to type 1 diabetes. Moreover,
the data suggest that postdiagnosis inter-
ventionsshouldbedevelopedforapplica-
tion as close to the diagnosis of type 1
diabetes as possible.
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